Paul Hartmann AG — Cyborg Score 7/10

Strategic Profile

Founded in 1818 and headquartered in Heidenheim, Germany, Paul Hartmann holds a strong competitive position in the aging-population-driven healthcare sector. The company's diversified product portfolio across wound management, incontinence care, and infection prevention positions it well in essential healthcare markets with recurring demand.

Cyborg Score Rationale

In 2024, revenue reached €2.43 billion with earnings increasing 281.58%, demonstrating strong operational improvement and market demand. The company's established brand portfolio, global distribution, and focus on essential healthcare products provide resilience and growth potential.

Top Insights

• 2024 revenue of €2.43 billion represents a 2.46% increase year-over-year
• Three-segment structure (Incontinence, Wound Care, Infection Management) provides diversified revenue streams
• Strong brand portfolio including MoliCare, Sterillium, Veroval, and Zetuvit
• Global presence with operations spanning Europe, Africa, Asia-Pacific, Americas and Middle East

Named Competitors

• Incontinence and Wound Care Products — Specialized medical devices for ostomy, continence, and wound care
• Medical and Surgical Supplies — Healthcare products including continence care and wound care
• Medical Technology — Pharmaceuticals and medical device manufacturer

Recent Developments

• (March 2025) Q4 2025 Earnings Release scheduled
• (2024) Significant earnings improvement with 281.58% increase
• (2024) Continued revenue growth and market position strengthening

Open the full interactive Paul Hartmann AG report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.